More on NRSN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.5 Score)

Upcoming Events

- Earnings (5/28/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Neurosense Therapeutics (NQ:NRSN)
Delayed: 0.87 +0.02 (2.35%)
Prev. Close $0.85  
Open$0.86 
52 Wk High$ 
52 Wk Low$ 
Day High$0.90 
Day Low$0.84 
P/E N/A  
EPS$ 
Volume67,701 

Friends, Peers and Foes (?): H1Z NRSNW (more...)

Feb 18, 2026 09:21 AM Form 6-K NeuroSense Therapeutics For: Feb 18
Feb 18, 2026 09:05 AM NeuroSense reports 65% death risk reduction in ALS trial
Feb 18, 2026 09:05 AM NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
Feb 13, 2026 04:35 PM Form 6-K NeuroSense Therapeutics For: Feb 13
Feb 9, 2026 09:31 AM Form 6-K NeuroSense Therapeutics For: Feb 09
Feb 9, 2026 09:20 AM NeuroSense receives Australian patent for PrimeC drug composition
Feb 9, 2026 09:20 AM NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Jan 29, 2026 05:29 PM Form F-3 NeuroSense Therapeutics
Jan 21, 2026 08:30 AM NeuroSense receives US patent for Alzheimer's treatment through 2043
Jan 21, 2026 08:30 AM NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
View All Articles

Entities mentioned with NRSN

View All Entities